Get the Stockscreener App
2.60
11.86%
-0.35
After Hours:
2.61
0.010
+0.38%
Veru Inc stock is traded at $2.60, with a volume of 488.98K.
It is down -11.86% in the last 24 hours and down -31.58% over the past month.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.
See More
Previous Close:
$2.95
Open:
$2.95
24h Volume:
488.98K
Relative Volume:
2.72
Market Cap:
$38.11M
Revenue:
$6.66M
Net Income/Loss:
$-25.52M
P/E Ratio:
-2.1488
EPS:
-1.21
Net Cash Flow:
$-28.98M
1W Performance:
-31.58%
1M Performance:
-31.58%
6M Performance:
-49.42%
1Y Performance:
-65.95%
1-Day Range:
$2.53
$2.99
1-Week Range:
$2.53
$3.8131
52-Week Range:
$2.53
$14.20
Veru Inc Stock (VERU) Company Profile
Name
Veru Inc
Sector
Industry
Phone
(312) 595-9123
Address
2916 N. MIAMI AVENUE, MIAMI, FL
Compare VERU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VERU
Veru Inc
|
2.60 | 47.35M | 6.66M | -25.52M | -28.98M | -1.21 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Veru Inc Stock (VERU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-14-24 | Initiated | B. Riley Securities | Buy |
| Mar-28-24 | Initiated | Raymond James | Outperform |
| Jun-07-23 | Upgrade | Jefferies | Underperform → Hold |
| Apr-13-21 | Initiated | Jefferies | Buy |
| Feb-09-21 | Reiterated | H.C. Wainwright | Buy |
| Jan-21-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-20-19 | Initiated | Oppenheimer | Outperform |
| Jul-03-18 | Initiated | Maxim Group | Buy |
View All
Veru Inc Stock (VERU) Latest News
Will Veru Inc. (FMW) stock see valuation expansion2025 Fundamental Recap & AI Driven Stock Price Forecasts - newser.com
Custom watchlist performance reports with Veru Inc.Trade Performance Summary & Long-Term Capital Growth Strategies - newser.com
Automated trading signals detected on Veru Inc.Fed Meeting & Smart Money Movement Tracker - newser.com
How strong is Veru Inc. stock revenue growthMarket Risk Summary & Daily Profit Focused Stock Screening - newser.com
What to expect from Veru Inc. in the next 30 days2025 Volume Leaders & Growth Focused Entry Reports - newser.com
Using AI based signals to follow Veru Inc.July 2025 Recap & Free Fast Gain Swing Trade Alerts - newser.com
Using economic indicators to assess Veru Inc. potentialShort Setup & Real-Time Volume Triggers - newser.com
Can Veru Inc. stock sustain institutional interestEarnings Overview Summary & Risk Managed Trade Strategies - newser.com
Can Veru Inc. (FMW) stock double in coming yearsJuly 2025 Volume & Capital Efficient Trading Techniques - newser.com
Why Veru Inc. stock is favored by pension fundsJuly 2025 Fed Impact & Real-Time Chart Pattern Alerts - newser.com
Why retail investors favor Veru Inc. stockPrice Action & Reliable Entry Point Trade Alerts - newser.com
Is Veru Inc. (FMW) stock expanding market penetration2025 Risk Factors & Daily Profit Maximizing Tips - newser.com
Why Veru Inc. (FMW) stock stays undervaluedQuarterly Portfolio Report & Target Return Focused Picks - newser.com
Why pension funds invest in Veru Inc. (FMW) stockJuly 2025 Analyst Calls & Safe Entry Point Alerts - newser.com
Can trapped investors hope for a rebound in Veru Inc.Weekly Trade Review & AI Forecast Swing Trade Picks - newser.com
Will Veru Inc. (FMW) stock split increase liquidityPortfolio Risk Report & Entry Point Confirmation Alerts - newser.com
Can Veru Inc. stock deliver surprise earnings beatJuly 2025 Snapshot & Advanced Swing Trade Entry Plans - newser.com
Can Veru Inc. stock resist sector downturnsMarket Volume Summary & Smart Investment Allocation Insights - newser.com
Will Veru Inc. (FMW) stock issue positive guidanceJuly 2025 Catalysts & Consistent Income Trade Recommendations - newser.com
What analysts say about Veru Inc stockValue Traps to Avoid & Free Real-Time Trading Alerts Every Day - earlytimes.in
Veru Inc. to Present Key Findings on Enobosarm at ObesityWeek 2025 - Quiver Quantitative
Veru (NASDAQ: VERU) to present enobosarm data with GLP-1RA at ObesityWeek 2025 - Stock Titan
Will Veru Inc. (FMW) stock keep raising dividendsMarket Performance Recap & Weekly Return Optimization Alerts - newser.com
How to build a custom watchlist for Veru Inc.July 2025 Rallies & Low Drawdown Investment Strategies - newser.com
Veru prices $25.2 million public offering to fund clinical studies By Investing.com - Investing.com Canada
Veru Announces Public Offering to Raise $23.4 Million - TipRanks
Veru prices 1.4M shares at $3.00 in underwritten public offering - TipRanks
Veru announces pricing of $25M public offering - TipRanks
Veru stock tumbles after pricing public offering at $3 per share - Investing.com Nigeria
Veru stock tumbles after pricing public offering at $3 per share By Investing.com - Investing.com South Africa
Veru (VERU) Unveils Public Offering to Fuel Enobosarm Developmen - GuruFocus
Veru Announces Pricing of $25 Million Public Offering - The Manila Times
Veru (NASDAQ: VERU) prices offering at $3.00; expected gross proceeds of $25.2M - Stock Titan
Does Veru Inc. qualify in momentum factor screeningWeekly Profit Recap & Verified Momentum Watchlists - newser.com
Veru Inc Stock (VERU) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):